Silence Therapeutics is a biotechnology company focused on discovering and developing short interfering RNA (siRNA) therapeutics to inhibit the expression of specific target genes in diseases with significant unmet medical need. The company utilizes its proprietary mRNAi GOLD platform to design siRNA molecules that silence disease-associated genes, primarily in the liver. Its pipeline includes divesiran (SLN124) for polycythemia vera, zerlasiran (SLN360) for cardiovascular disease associated with high lipoprotein(a), and SLN098 for obesity. Other candidates include SLN548 for complement-mediated renal diseases, SLN365 for hypercholesterolemia, and SLN312 for lipid metabolism, the latter of which was previously under collaboration with AstraZeneca. The company serves patients with rare and common conditions, including hematological, cardiometabolic, and metabolic disorders, and has received regulatory designations from the FDA and European Commission for specific indications.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage silence-therapeutics.com
Sector Healthcare IR page silence-therapeutics.com/investors
Tags
sirna therapeutics, rna interference, gene silencing, hematology, cardiometabolic diseases, obesity, lipid metabolism, rare diseases, polycythemia vera, hypercholesterolemia, mRNAi GOLD, divesiran, SLN124, SLN548, zerlasiran, SLN360, SLN312, SLN365, SLN098
Press page —

Metrics

Valuation  
Market cap $ 2.04B
Market cap (USD) $ 2.04B
P/E -29.54
PEG —
P/BV 9.49
P/S —
P/OCF -46.20
P/FCF -46.20
Dividend yield —
Turnover / mcap —
Returns  
ROE -90.3%
ROI -173.4%
ROIC -133.7%
Profit margin -15,851.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score -77.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 559K 43.258M 32.128M 20.58M 17.111M 7.076M
Net profit -88.612M -45.309M -54.781M -47.612M -54.317M -42.036M
Free cash flow -62.326M -67.851M -49.879M -53.617M 7.574M -14.578M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 6.08 6.88 17.37 15.25 23.89 20.41
Price performance 12m -0.12 -0.6 0.14 -0.36 0.17 —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 290,000 972,000 0.00
↳ YoY growth +235.2% -100.0%
Lease liabilities (USD) — — — — 346,000 117,000 160,000
Cash and deposits (USD) — — — — 68.8M 121M 11.3M
Intangible assets (USD) — — — — — 312,000 288,000
Right-of-use assets (USD) — — — — 370,000 157,000 167,000
Cash flow detail
Operating cash flow (USD) — — — -57M -49.5M -67.6M -62.3M
Purchases of property, plant and equipment (USD) — — — -173,000 -56,000 -211,000 -55,000
Purchases of intangible assets (USD) — — — -372,000 — — —
Change in receivables (cash effect) (USD) — — — -723,000 392,000 -904,000 1.02M
Income taxes paid (cash effect) (USD) — — — — 801,000 433,000 -637,000
Share-based compensation (USD) — — — 12.7M 16.3M 16.3M 8.07M
Operating cash flow before change in receivables (USD) — — — -56.3M -49.9M -66.7M -63.3M
Free cash flow (OCF - PPE - intangibles) (USD) — — — -57.6M -49.5M -67.9M -62.3M
Income detail
Research and development expense (GBP) 13.3M 20.2M 30.8M 35.6M 44M 67.9M 67.8M
Total comprehensive income (USD) — — — -50.4M -53.4M -46.4M -79.8M
Comprehensive income to owners (USD) — — — -50.4M -53.4M -46.4M -79.8M
Reported Mar 17, 2022 Mar 17, 2022 Mar 17, 2022 Feb 27, 2025 Feb 27, 2025 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

12 November 2026

LONDON, Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided an update on other recent business achievements.

Recent Business Highlights

• On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy silencing TMPRSS6, in polycythemia vera, supporting a potentially best-in-class profile with once-every-three-month dosing.

• SANRECO Phase 2 results have been accepted for oral presentation at the upcoming American Society of Hematology (ASH) 2026 Annual Meeting, being held December 12-15, 2026 in New Orleans, LA. You can find the presentation details here.

• On October 19, 2026, Silence announced (press release) that it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to the satisfaction of customary closing conditions.

Investor Contacts

Home / Investors / Resources / Investor Contacts

Corporate Headquarters

UK

12 Hammersmith Grove
London, W6 7AP

Germany

Robert-Rossle-Str. 10
D-13125 Berlin
Tel: [+49 30 9489 2800](tel:+49 30 9489 2800)

US

221 River Street, 9th Floor
Hoboken, NJ 07030

Investor Contact

Gem Hopkins
Head of IR & Corporate Communications
[email protected]

Silence Therapeutics Logo

Stay Connected

Quick Links

Quick Links

Home / Investors / Resources / Information Request Form

The following errors must be corrected

  • First Name is required
  • Last Name is required
  • Company Name is required
  • Email Address is required
  • Phone Number is required
  • State/ Province is required
  • Country is required
  • Are you an investor? is required

First Name*

Last Name*

Company Name*

Email Address*

Phone Number*

State/ Province*

Country*AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua & BarbudaArgentinaArmeniaAustraliaAustriaAzerbaijanBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBhutanBoliviaBosnia & HerzegovinaBotswanaBrazilBruneiBulgariaBurkina FasoBurmaBurundiCambodiaCameroonCanadaCape VerdeCentral African RepublicChadChileChinaColombiaComorosCongo (Brazzaville)Congo (Kinshasa)Costa RicaCôte d'IvoireCroatiaCubaCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFijiFinlandFranceGabonGambiaGeorgiaGermanyGhanaGreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMexicoMicronesiaMoldovaMonacoMongoliaMoroccoNamibiaNauruNepalNetherlandsNew ZealandNicaraguaNigerNigeriaNorth KoreaNorwayOmanPakistanPalauPanamaPapua New GuineaParaguayPeruPhilippinesPolandPortugalQatarRomaniaRussiaRwandaSaint LuciaSaint Vincent and the GrenadinesSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSeychellesSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth KoreaSpainSri LankaSt. Kits and NevisSudanSurinameSwazilandSwedenSwitzerlandSyriaTajikistanTanzaniaThailandThe BahamasTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamWestern SamoaYemenZaireZambiaZimbabwe

Document Request

  • Annual Report
  • Annual Proxy

Are you an investor?*

  • I am an investor
  • I am not an investor

Submit

Silence Therapeutics Logo

Stay Connected

Quick Links

Quick Links

Prompts

Silence Therapeutics Plc (ticker SLN), listed in United States.

Company History

Date Change Detail
Dec 31, 2024 Reporting currency Its US reports are in USD instead of GBP from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding Silence Therapeutics Plc

ETF Weight in ETF Shares Market value As of
APIE 0.01% 8,053 $ 108.957K Aug 31, 2026